Status:
COMPLETED
Biomarker and Thrombogenicity Assessment in Cardiopulmonary Bypass Surgery Utilizing Acute Normovolemic Hemodilution
Lead Sponsor:
Inova Health Care Services
Collaborating Sponsors:
Instrumentation Laboratory
Conditions:
Bleeding Reduction
Eligibility:
All Genders
18-85 years
Brief Summary
This study will help enhance current understanding of the impact of Acute Normovolemic Hemodilution (ANH) administration on transfusion requirements post cardiac surgery, the effect of this procedure ...
Detailed Description
Acute Normovolemic Hemodilution (ANH) involves the removal of the patients own blood immediately at the induction of anesthesia and replacement of this blood intraoperatively with an equivalent volume...
Eligibility Criteria
Inclusion
- . Subject is 18-85 years old.
- . Subject is hemodynamically stable
- . The subject is able to read and has signed and dated the informed consent document including Health Insurance Portability and Accountability Act of 1996 (HIPAA) authorization permitting release of personal health information as approved by the investigator's Institutional Review Board (IRB).
Exclusion
- . Hematocrit \<30 at baseline
- . Insufficient (Low) on pump hematocrit of \< 21%
- . Patient is hemodynamically unstable
- . Patient requiring an emergency procedure
- . Left main coronary artery stenosis with evidence of hemodynamic instability (e.g.. hypotension, ST segment elevations on electrocardiogram)
- . Aortic valve stenosis with evidence of hemodynamic instability (e.g.. hypotension, ST segment elevations on electrocardiogram)
Key Trial Info
Start Date :
March 19 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 17 2019
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT03326323
Start Date
March 19 2018
End Date
October 17 2019
Last Update
January 13 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Inova Heart and Vascular Institute
Falls Church, Virginia, United States, 22042